Utilizarea glucocorticoizilor în infecția cu SARS CoV 2: pro și contra

Nicolae Bacinschi; Lucia Ţurcan; Lilia Podgurschi; Ina Gutu; Tatiana Covalschi; Maria Mihalachi-Anghel; Marin Chianu; Anastasia Caracas; Eugenia Vasilache

Utilizarea glucocorticoizilor în infecția cu SARS CoV 2: pro și contra

Autori

Nicolae Bacinschi Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0003-4854-5715
Lucia Ţurcan Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0003-1904-9464
Lilia Podgurschi Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0002-5922-7838
Ina Gutu Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0002-7839-5415
Tatiana Covalschi Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“
Maria Mihalachi-Anghel Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0001-7428-5668
Marin Chianu Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0003-0515-5178
Anastasia Caracas Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0009-0003-6673-4322
Eugenia Vasilache Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“

Cuvinte cheie:

infecția SARS CoV-2, COVID-19, glucocorticoizii, furtuna citokinică, eficacitatea, siguranţă

Rezumat

Tratamentul infecției cu SARS CoV-2 constituie o problemă majoră a medicinei contemporane, cauzată de absența medicamentelor antivirale specifi ce. Tentativele de utilizare a multor grupe de preparate au cunoscut unele succese și insuccese. Abordarea patofi ziologică a raționalității folosirii medicamentelor constituie baza efi cacității și siguranței tratamentului. Glucocorticoizii constituie o grupă de preparate capabilă să rezolve problemele de sănătate în situațiile grave și critice. Medicii practicieni, în ciuda absenței datelor bazate pe dovezi, continuă utilizarea corticosteroizilor în situațiile critice în baza proprietăților farmacologice și experienței acumulate. În infecția cu SARS CoV-2, inițial, la începutul pandemiei, nu era recomandată utilizarea glucocorticoizilor, iar ulterior, în baza studiilor clinice efectuate, Organizația Mondială a Sănătății a emis un șir de dispoziții referitoare la raționalitatea folosirii lor printr-o abordare individualizată. Aceasta din urmă presupune determinarea momentului inițierii, selectării preparatului, dozelor și duratei de tratament. Momentul- cheie în acest context îl constituie timpul declanșării furtunii citokinice (săptămâna a doua de la debutul simptomelor), asupra căreia este îndreptată administrarea glucocorticoizilor.

Referințe

1. Ahmed M.H., Hassan A. Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review. In: SN Compr. Clin. Med. 2020 Oct 31:1-10. doi: 10.1007/s42399-020-00610-8. Epub ahead of print. PMID: 33163859; PMCID: PMC7599121.

2. Alessi J., de Oliveira G.B., Schaan B.D. et al. Dexamethasone in the era of COVID-19: friend or foe? An essay on the eff ects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. In: Diabetol. Metab. Syndr. 2020 Sep 7;12: 80. https://doi.org/10.1186/s13098-020-00583-7

3. Burrage D.R., Koushesh S., Sofat N. Immunomodulatory Drugs in the Management of SARS-CoV-2. In: Front. Immunol. 2020 Aug 13;11: 1844. PMID: 32903555; PMCID: PMC7438578. https://doi.org/10.3389/fimmu.2020.01844

4. Choudhary S., Sharma K., Silakari O. The interplay between infl ammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options. In: Microb. Pathog. 2020 Dec 2;150: 104673. https://doi.org/10.1016/j.micpath.2020.104673

5. European Medicines Agency. Dexamethasone in hospitalised patients with COVID-19. EMA/509632/2020.17 September 2020. Procedure number: EMEA/H/A5(3)/1500.

6. Halacli B., Topeli A. Treatment of the Cytokine Storm in COVID-19. In: J. Crit. Intensive Care. 2020; 11(Suppl. 1): 36−40.

https://doi.org/10.37678/dcybd.2020.2434

7. Ismini A.V., Holger H. The Role of Glucocorticoids in the Management of COVID-19 Playlist. In: Hormone and Metabolic Research 2020.

https://doi.org/10.1055/a-1300-2550

8. Kronbichler A., Eff enberger M., Eisenhut M. et al. Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view. In: Autoimmun Rev. 2020 Jul; 19(7): 102570. https://doi.org/10.1016/j.autrev.2020.102570

9. Lam S., Lombardi A., Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. In: Eur. J. Pharmacol. 2020 Nov 5; 886:173451. https://doi.org/10.1016/j.ejphar.2020.173451

10. Lariccia V., Magi S., Serfi lippi T. et al. Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review. In: J. Clin. Med. 2020 Dec 12; 9(12): 4021. https://doi.org/10.3390/jcm9124021

11. Li L., Li R., Wu Z. et al. Therapeutic strategies for critically ill patients with COVID-19. In: Ann. Intensive Care. 2020 Apr; 10, 45. https://doi.org/10.1186/s13613-020-00661-z

12. Matthay M.A., Thompson B.T. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. In: Lancet. Respir. Med. 2020 Dec; 8(12): 1170-1172. https://doi.org/10.1016/S2213-2600(20)30503-8

13. Mehta Y., Dixit S.B., Zirpe K.G. et al. Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management Considerations. In: Indian Journal of Critical Care Medicine (2020): 10.5005/jp-journals10071-23415.

14. Mussini C., Falcone M., Nozza S. et al. Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT), In: Clinical Microbiology and Infection, 2020, 22 dec., https://doi.org/10.1016/j.cmi.2020.12.011

15. Neupane K., Ahmed Z., Pervez H. et al. Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts. In: Cureus. 2020 Jun 26; 12(6): e8845. https://doi.org/10.7759/cureus.8845

16. Panettieri R.A., Schaafsma D., Amrani Y. et al. Nongenomic Eff ects of Glucocorticoids: An Updated View. In: Trends Pharmacol. Sci. 2019 Jan; 40(1): 38-49. https://doi.org/10.1016/j.tips.2018.11.002

17. Pasin L., Navalesi P., Zangrillo A. et al. Corticosteroids for Patients With Coronavirus Disease 2019 (COVID19) With Diff erent Disease Severity: A Meta-Analysis of Randomized Clinical Trials. In: Journal of Cardiothoracic and Vascular Anesthesia. 2021; 35: 578-584. https://doi.org/10.1053/j.jvca.2020.11.057

18. Quatrini L., Ugolini S. New insights into the cell-and tissue-specifi city of glucocorticoid actions. In: Cell. Mol. Immunol. (2020). https://doi.org/10.1038/s41423-020-00526-2

19. Quirch M., Lee J., Rehman S. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review. In: J. Med. Internet Res. 2020 Aug 13; 22(8): e20193. https://doi.org/10.2196/20193

20. Razmi M., Hashemi F., Gheytanchi E. et al. Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review. In: International Immunopharmacology. 2020 November; 88: 106942. https://doi.org/10.1016/j.intimp.2020.106942

21. Rizk J.G., Kalantar-Zadeh K., Mehra M.R. et al. Pharmaco-Immunomodulatory Therapy in COVID-19. In: Drugs. 2020 Sep; 80(13): 1267-1292. https://doi.org/10.1007/s40265-020-01367-z

22. Ruiz-Irastorza G., Pijoan J-I., Bereciartua E. et al. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data. In: PLoS ONE. 2020; 15(9): e0239401. https://doi.org/10.1371/journal.pone.0239401

23. Sahebnasagh A., Avan R., Saghafi F.et al. Pharmacological treatments of COVID-19. In: Pharmacol Rep. 2020 Aug 20:1-33. https://doi.org/10.1007/s43440-020-00152-9

24. Shyr Z.A., Gorshkov K., Chen C.Z., Zheng W. Drug Discovery Strategies for SARS-CoV-2. In: Journal of Pharmacology and Experimental Therapeutics. 2020 October, 375 (1) 127-138; https://doi.org/10.1124/jpet.120.000123

25. Silva T.F., Tomiotto-Pellissier F., Sanfelice R.A. et al. A 21st Century Evil: Immunopathology and New Therapies of COVID-19. In: Front Immunol. 2020 Oct 27; 11:562264. https://doi.org/10.3389/fimmu.2020.562264

26. Solinas C., Perra L., Aiello M. et al. A critical evaluation of glucocorticoids in the management of severe COVID-19. In: Cytokine Growth Factor Rev. 2020 Aug; 54:8-23. https://doi.org/10.1016/j.cytogfr.2020.06.012

27. Soy M., Keser G., Atagündüz P. et al. Cytokine storm in COVID-19: pathogenesis and overview of anti-infl ammatory agents used in treatment. In: Clin. Rheumatol. 2020 Jul; 39(7): 2085-2094. https://doi.org/10.1007/s10067-020-05190-5

28. Tang Y., Liu J., Zhang D. et al. Cytokine Storm in COVID19: The Current Evidence and Treatment Strategies. In: Front. Immunol. 2020; 11:1708. https://doi.org/10.3389/fimmu.2020.01708

29. Tortajada C., Colomer E., Andreu-Ballester J.C. et al. Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Eff ect of corticosteroids on mortality and intensive care unit admission in patients with COVID-19 according to patients' oxygen requirements. In: J. Med. Virol. 2020 27 October;1-7. https://doi.org/10.1002/jmv.26635

30. van Paassen J., Vos J.S., Hoekstra E.M. et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. In: Crit. Care. 2020 Dec 14; 24(1):696. https://doi.org/10.1186/s13054-020-03400-9

31. Wu C., Hou D., Du C. et al. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis. In: Crit. Care. 2020 Nov 10; 24(1):643. https://doi.org/10.1186/s13054-020-03340-4

32. Zhand S., Saghaeian J.M., Mohammadi S. et al. COVID19: The Immune Responses and Clinical Therapy Candidates. In: Int. J. Mol. Sci. 2020 Aug 3;21(15):5559. https://doi.org/10.3390/ijms21155559

33. Yang Li, Xian Zhou, Tao Li et al. Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study. In: Emerging Microbes & Infections, 2020; 9:1, 1869-1877, https://doi.org/10.1080/22221751.2020.1807885

34. Ye Q., Wang B., Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. In: Journal of infection. 2020; 80 (6): 607-613. https://doi.org/10.1016/j.jinf.2020.03.037

Descărcări

Publicat

17.06.2026

Număr

Nr. 1(88) (2021)

Secțiune

Articole

Licență

Această lucrare este licențiată în temeiul Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Cum cităm

[1]

Bacinschi, N. et al. 2026. Utilizarea glucocorticoizilor în infecția cu SARS CoV 2: pro și contra. Public Health Economy and Management in Medicine. 1(88) (Jun. 2026), 4–20.